Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study

Several compounds based on short chain fatty acids and/or probiotics/prebiotics have shown promising results in the therapy of ulcerative colitis (UC), possibly due to its key role in restoring gut homeostasis as well as intestinal barrier integrity. Here, we investigated the efficacy of a patented...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gian Paolo Caviglia, Federico De Blasio, Marta Vernero, Angelo Armandi, Chiara Rosso, Giorgio Maria Saracco, Elisabetta Bugianesi, Marco Astegiano, Davide Giuseppe Ribaldone
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	complementary therapy inflammatory bowel diseases (IBD) maintaining therapy mesalamine mesalazine short chain fatty acids (SCFAs) Medicine R
Acceso en línea:	https://doaj.org/article/54ded8b0b01241d3833fa21321fb319e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:54ded8b0b01241d3833fa21321fb319e
record_format	dspace
spelling	oai:doaj.org-article:54ded8b0b01241d3833fa21321fb319e2021-11-11T17:35:39ZEfficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study10.3390/jcm102149612077-0383https://doaj.org/article/54ded8b0b01241d3833fa21321fb319e2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4961https://doaj.org/toc/2077-0383Several compounds based on short chain fatty acids and/or probiotics/prebiotics have shown promising results in the therapy of ulcerative colitis (UC), possibly due to its key role in restoring gut homeostasis as well as intestinal barrier integrity. Here, we investigated the efficacy of a patented preparation based on calcium butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and fructooligosaccharides (FEEDColon<sup>®</sup>, Princeps, Cuneo, Italy) in maintaining remission and improving subjective symptoms and inflammatory indices in patients with UC receiving 5-ASA therapy. A total of 42 patients were prospectively recruited and randomized in 21 patients receiving combination therapy with mesalamine (5-ASA) plus FEEDColon<sup>®</sup> and 21 patients treated with standard 5-ASA therapy. Patients were assessed at baseline, at 6-month, and 12-month follow-up (FU). Therapeutic success (defined as Mayo partial score ≤ 2 and faecal calprotectin (FC) < 250 µg/g at 12-month FU) was reached by 32 (76%) patients: 20 (95%) among those treated with 5-ASA + FeedColon<sup>®</sup>, and 12 (57%) among those treated with 5-ASA only (<i>p</i> = 0.009). Consistently, patients treated with combination therapy improved subjective symptoms (quality of life, abdominal pain, and stool consistency) and reduced FC values, while those treated with 5-ASA alone, improved neither subjective symptoms nor FC during the FU. In conclusion, FEEDColon<sup>®</sup> supplementation appears to be a valid add-on therapy for the maintenance of remission in patients with UC. Further multicentre, placebo-controlled, double-blind clinical trials are needed to validate our results on larger cohorts of patients with UC.Gian Paolo CavigliaFederico De BlasioMarta VerneroAngelo ArmandiChiara RossoGiorgio Maria SaraccoElisabetta BugianesiMarco AstegianoDavide Giuseppe RibaldoneMDPI AGarticlecomplementary therapyinflammatory bowel diseases (IBD)maintaining therapymesalaminemesalazineshort chain fatty acids (SCFAs)MedicineRENJournal of Clinical Medicine, Vol 10, Iss 4961, p 4961 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	complementary therapy inflammatory bowel diseases (IBD) maintaining therapy mesalamine mesalazine short chain fatty acids (SCFAs) Medicine R
spellingShingle	complementary therapy inflammatory bowel diseases (IBD) maintaining therapy mesalamine mesalazine short chain fatty acids (SCFAs) Medicine R Gian Paolo Caviglia Federico De Blasio Marta Vernero Angelo Armandi Chiara Rosso Giorgio Maria Saracco Elisabetta Bugianesi Marco Astegiano Davide Giuseppe Ribaldone Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
description	Several compounds based on short chain fatty acids and/or probiotics/prebiotics have shown promising results in the therapy of ulcerative colitis (UC), possibly due to its key role in restoring gut homeostasis as well as intestinal barrier integrity. Here, we investigated the efficacy of a patented preparation based on calcium butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and fructooligosaccharides (FEEDColon<sup>®</sup>, Princeps, Cuneo, Italy) in maintaining remission and improving subjective symptoms and inflammatory indices in patients with UC receiving 5-ASA therapy. A total of 42 patients were prospectively recruited and randomized in 21 patients receiving combination therapy with mesalamine (5-ASA) plus FEEDColon<sup>®</sup> and 21 patients treated with standard 5-ASA therapy. Patients were assessed at baseline, at 6-month, and 12-month follow-up (FU). Therapeutic success (defined as Mayo partial score ≤ 2 and faecal calprotectin (FC) < 250 µg/g at 12-month FU) was reached by 32 (76%) patients: 20 (95%) among those treated with 5-ASA + FeedColon<sup>®</sup>, and 12 (57%) among those treated with 5-ASA only (<i>p</i> = 0.009). Consistently, patients treated with combination therapy improved subjective symptoms (quality of life, abdominal pain, and stool consistency) and reduced FC values, while those treated with 5-ASA alone, improved neither subjective symptoms nor FC during the FU. In conclusion, FEEDColon<sup>®</sup> supplementation appears to be a valid add-on therapy for the maintenance of remission in patients with UC. Further multicentre, placebo-controlled, double-blind clinical trials are needed to validate our results on larger cohorts of patients with UC.
format	article
author	Gian Paolo Caviglia Federico De Blasio Marta Vernero Angelo Armandi Chiara Rosso Giorgio Maria Saracco Elisabetta Bugianesi Marco Astegiano Davide Giuseppe Ribaldone
author_facet	Gian Paolo Caviglia Federico De Blasio Marta Vernero Angelo Armandi Chiara Rosso Giorgio Maria Saracco Elisabetta Bugianesi Marco Astegiano Davide Giuseppe Ribaldone
author_sort	Gian Paolo Caviglia
title	Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
title_short	Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
title_full	Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
title_fullStr	Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
title_full_unstemmed	Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
title_sort	efficacy of a preparation based on calcium butyrate, <i>bifidobacterium bifidum</i>, <i>bifidobacterium lactis</i>, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: a prospective observational study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/54ded8b0b01241d3833fa21321fb319e
work_keys_str_mv	AT gianpaolocaviglia efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy AT federicodeblasio efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy AT martavernero efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy AT angeloarmandi efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy AT chiararosso efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy AT giorgiomariasaracco efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy AT elisabettabugianesi efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy AT marcoastegiano efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy AT davidegiusepperibaldone efficacyofapreparationbasedoncalciumbutyrateibifidobacteriumbifidumiibifidobacteriumlactisiandfructooligosaccharidesinthepreventionofrelapseinulcerativecolitisaprospectiveobservationalstudy
_version_	1718432064616792064

Efficacy of a Preparation Based on Calcium Butyrate, <i>Bifidobacterium bifidum</i>, <i>Bifidobacterium lactis</i>, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study

Ejemplares similares